Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 209

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 209
---
%                                 |
| John Sundy(a)(f)            | 100%                             | 88%                                  |
| Yann Tran                   | 100%                             | 100%                                 |
| Emile Voest                 | 100%                             | 100%                                 |
| Antoine Yver(g)             | 100%                             | 100%                                 |

| Average attendance rateat Board meetings | Average attendance rateat Committee meetings |
| 98%                                      | 97%                                          |

(a) Clotilde Delbos, Anne-Françoise Nesmes and John Sundy joined the Board during 2024. (b) Clotilde Delbos joined the Audit Committee and Compensation Committee in April 2024, and attended the four and two meetings, respectively, held subsequent to her appointment. (c) Anne-Françoise Nesmes joined the Audit Committee in April 2024, and attended the four meetings held subsequent to her appointment. (d) Gilles Schnepp left the Board on December 31, 2024. He did not take part to the Board meetings dedicated to the Opella separation. (e) Diane Souza and Thomas Südhof left the Board during 2024. (f) John Sundy joined the Scientific Committee in April 2024, and attended three meetings out of four held subsequent to his appointment. (g) Antoine Yver joined the Strategy Committee in April 2024, and attended the three meetings held subsequent to his appointment. Directors who were absent from some meetings provided clear and substantiated explanations for their absence, which related mainly to personal matters or to unscheduled meetings called at short notice (especially where sudden developments on an ongoing project necessitated a Board meeting). Declarations by Board members (including convictions and conflicts of interest) As of December 31, 2024, no corporate officer has been the subject of any conviction or court order, or been associated with any bankruptcy or winding-up order. As of this day, there is no potential conflict of interest between any corporate officer and Sanofi. As of December 31, 2024, the members of our Board of Directors collectively held (directly, or via the employee share ownership fund associated with the Group savings scheme) 155,251 of our shares, representing 0.012% of our share capital. Service agreements entered into with Board members Except as otherwise described below, there are no existing service agreements or arrangements between the Company or any of its subsidiaries, and any Board member or corporate officer